Frequency: SubQ NAD protocols are quite flexible
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function

' I didn't really have any choice: It was that or my symptoms coming back ' A GLP-1 medication gave 23-year-old Gabriela Pena something she'd seldom had since she was 13: her period
fermentum GB102 strain reduced the weight regain when discontinuing dulaglutide drugs, as well as maintaining muscle mass, positioning it as a potential solution to this widespread problem
Your physician can also use a titration schedule to help make this decision